Abstract
ProMortionⓇ (PM) was developed as an animal supplement, containing glucosamine HCL, collagen peptides, N-acetylcysteine, bioflavanol, and vitamin C as main components, for the treatment of degenerative joint disease (DJD) in dogs mainly through an anti-inflammatory mechanism. This study assessed the inflammatory status in adjuvant arthritis model rats given PM. Adjuvant arthritis was induced in Lewis rats by a single intradermal injection of adjuvant containing 0.5 mg of heat-inactivated Mycobacterium tuberculosis in the right footpad. Five arthritis model rats were allocated to the following groups: no PM treatment (N-PM group), treatment with the usual dose of PM (PM group), treatment with triple the usual dose of PM (3PM group), or treatment with L-methionine (LM group) as an active control. Paw inflammation scores, the rate of paw volume increase obtained using X-ray computerized tomography images, and serum nitric oxide (NO) and prostaglandin E2（PGE2）levels as determined using assay kits were obtained and compared among the groups to assess arthritis. Inflammation scores and the paw volume increase rate were lower in the PM, 3PM, and LM groups than in the N-PM group. The measured values of NO and PGE2 were significantly lower in the PM, 3PM, and LM groups than in the N-PM group. There were no significant differences in these parameters among the PM, 3PM, and LM groups. Our results thus indicate that PM has anti-inflammatory actions comparable to those of LM, and that PM may serve as a treatment option for DJD in dogs.
